Talennis approved for treating recurrent or metastatic cervical cancer in adult patients.

On June 8th, Zaiding Pharmaceuticals Limited announced that the National Medical Products Administration had approved the market authorization application of Tislel's biological product for the treatment of adult patients with recurrent or metastatic cervical cancer that has progressed during or after chemotherapy. This approval was based on the results of the global, randomized, phase 3 innovaTV 301 clinical study. The study met its primary endpoint, showing that compared to chemotherapy, pembrolizumab demonstrated a benefit in overall survival in previously treated adult patients with recurrent or metastatic cervical cancer, including in an exploratory subgroup of Chinese patients.